Human Lysozyme Goat Milk in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
Status:
Withdrawn
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This randomized pilot phase I trial studies the side effects of human lysozyme goat milk in
treating patients with blood cancer undergoing a donor stem cell transplant. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells
(called graft-versus-host disease). Giving human lysozyme goat milk to patients undergoing a
donor stem cell transplant may stop this from happening.